2022
DOI: 10.22541/au.165580620.03886383/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

CRISPR and CAR-T, NK Current application and future perspective

Abstract: Chimeric Antigen Receptor T-cells represent a breakthrough in personalized cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition, signaling, and stimulatory domains are used to reprogram T-cells to target tumor cells for destruction. Despite the success of this approach in refractory B-cell malignancies, optimal potency of CAR T-cell therapy for many other cancers, particularly solid tumors, has not been achieved. NK cells are powerful cytotoxic lymphocytes specialized in recog… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 47 publications
(47 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?